Evidence map›Paper›PMID 38613700›Full record

ArticleCell biochemistry and biophysics2024

Protopanaxadiol Targeting Membrane Induces HepG2 Cell Apoptosis Via Raft-like Formation and Tubulation Disruption.

Yue Wang, Yadi Wang, Xueling Li, Yu Gao, Xiaohong Pan, Junhong Lü

Abstract read
PubMed Publisher
In one paragraph

Article in Cell biochemistry and biophysics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 95% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Yue WangShanghai Institute of Applied Physics, Chinese Academy of Sciences, Shanghai, 201203, China.
Yadi WangCollege of Pharmacy, Binzhou Medical University, Yantai, 264003, China.
Xueling LiShanghai University of Medicine and Health Sciences, Shanghai, 201318, China.
Yu GaoCollege of Pharmacy, Binzhou Medical University, Yantai, 264003, China.
Xiaohong PanCollege of Pharmacy, Binzhou Medical University, Yantai, 264003, China. panxiaohong@bzmc.edu.cn.
Junhong LüShanghai Institute of Applied Physics, Chinese Academy of Sciences, Shanghai, 201203, China. lvjunhong@jnl.ac.cn.
Binzhou University · CNBinzhou Medical University · CNShanghai University of Medicine and Health Sciences · CN

Funding

NSAF Joint Fund of the National Natural Science Foundation of China U2230110
6 · The paper itself

Abstract

Protopanaxadiol (PPD), which has a molecular structure similar to cholesterol, is a potent anticancer agent that has been proposed to target the lipid membrane for the pharmacological effects. However, the underlying mechanism by which PPD modulates the cell membrane leading to cancer cell death is not be fully understood. In this work, we used single cell infrared spectroscopy, scanning electron microscopy and confocal microscopy to investigate the effects of PPD on human hepatocellular carcinoma (HepG2) cells, focusing on the change in membrane structure. We found that PPD significantly reduced the number of membrane tubules over the course of treatment. Interestingly, the addition of PPD could promote the formation of lipid raft-like domains (PPD rafts) and even restore the domain disruption caused by methyl-beta-cyclodextrin depletion of membrane cholesterol. In addition, PPD pre-treatment may increase the induction effect of FasL, which impairs cell viability, although it does not appear to be beneficial for Fas clustering in the PPD rafts. Collectively, these results highlight a non-classical mechanism by which PPD induces HepG2 apoptosis by directly affecting the physical properties of the cell membrane, providing a novel insight into understanding membrane-targeted therapy.

Indexed as

ApoptosisMembrane MicrodomainsSapogeninsAntineoplastic Agentsbeta-CyclodextrinsCell SurvivalCholesterolFas Ligand Proteinfas ReceptorHep G2 CellsHumansAntineoplastic Agentsbeta-CyclodextrinsCholesterolFas Ligand Proteinfas Receptormethyl-beta-cyclodextrinprotopanaxadiolSapogeninsHepG2 cellProtopanaxadiolRaft-like structureTargeting membraneTubulation

Identifiers

PMID38613700
OpenAlexW4394786238

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.